Monday, October 3, 2011

CKD Stage 4 Study

Our site is now participating in an important clinical study for persons with Type 2 Diabetes and Stage 4 chronic kidney disease (CKD).
This study called BEACON is being conducted around the world at multiple research sites.

At this time our site is the only active site in northern Ohio conducting this study for people with Type 2 Diabetes and Stage 4 CKD.

Stage 4 CKD is defined as a severe decrease in kidney function with 
an estimated glomerular filtration rate  (GFR)  
                                           between 15-29 (mL/min/1.73 m2).
A GFR below 15 generally requires dialysis to treat the kidney failure.
GFR declines with age but a normal value in a young adult is above 90.

In the U.S., diabetes is the most common cause of chronic kidney disease requiring dialysis. Despite our best efforts, most people with Stage 4 CKD have a worsening in their kidney function and will need dialysis or kidney transplant.

Bardoxolone methyl is an oral agent being investigated for treatment of CKD in diabetes. Results from a recent clinical study have shown encouraging results. 
Bardoxolone methyl is being studied in BEACON.

Interested persons can call our office at 440-266-5005 or 440-266-5000  to see if they qualify or simply to learn more.
You can also visit this link  to read more about this study.

No comments:

Post a Comment